SciELO - Scientific Electronic Library Online

 
vol.23 special issuePosition paper. Glucocorticoid and Cardiac Management in Patients with Duchenne Muscular DystrophyPrescription of Physical Activity in the Management of Patients with Duchenne Muscular Dystrophy author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Ciencias de la Salud

Print version ISSN 1692-7273On-line version ISSN 2145-4507

Abstract

RIVERA-NIETO, Carolina et al. Interpretation of Genetic Tests and Biomarkers in Duchenne Muscular Dystrophy. Rev. Cienc. Salud [online]. 2025, vol.23, n.spe, e23e5.  Epub Apr 22, 2025. ISSN 1692-7273.  https://doi.org/10.12804/revistas.urosario.edu.co/revsalud/a.13656.

Among the main characteristics of Duchenne muscular dystrophy (DMD) are the damage of muscle fibers during contraction, subsequent chronic muscle damage, inflammation, and subsequent replacement of muscle fibers by fibrous tissue. Biomarkers of the disease can reflect these types of alterations. Biomarkers in DMD are helpful for diagnosis, follow-up, and evaluation of the response to treatment. The indication for requesting different biomarkers varies according to the age and natural history of the disease, and their correct use allows for an adequate therapeutic approach, correct follow-up, and successful rehabilitation. The present review describes the different types of biomarkers and diagnostic methods used in patients with DMD and recommends their appropriate use according to their age and natural history of the disease.

Keywords : Duchenne muscular dystrophy; biomarkers; genetic testing.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )